FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes

被引：3

作者：

Montesinos, Pau ^{[1
]}

de la Rubia, Javier ^{[1
]}

Orti, Guillermo ^{[1
]}

Sanz, Jaime ^{[1
]}

Martinez, David ^{[1
]}

Mendoza, Ninotchka ^{[2
]}

Scaff, Miguel ^{[1
]}

Paciello, Mariliz ^{[1
]}

Romero, Monica ^{[1
]}

Martin, Guillermo ^{[1
]}

Lorenzo, Ignacio ^{[1
]}

Martinez, Jesus ^{[1
]}

Algarra, Lorenzo ^{[1
]}

Jarque, Isidro ^{[1
]}

Perez-Sirvent, Mariluz ^{[1
]}

Sanz, Guillermo ^{[1
]}

Sanz, Miguel A. ^{[1
]}

机构：

[1] Hosp Univ La Fe, Valencia, Spain

[2] CSS Arnulfo Arias Madrid, Panama City, Panama

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2866.2866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2866

引用

页码：843A / 843A

页数：1

共 50 条

[31] FLUDARABINE, CYTARABINE, GRANULOCYTE COLONY-STIMULATING FACTOR, AND IDARUBICIN (FLAG-IDA) FOR THE TREATMENT OF CHILDREN WITH POOR-PROGNOSIS ACUTE LEUKEMIA: The Hacettepe Experience
Tavil, Betul
Aytac, Selin
Balci, Yasemin Isik
Unal, Sule
Kuskonmaz, Baris
Yetgin, Sevgi
Gurgey, Aytemiz
Tuncar, Murat
Gumruk, Fatma
Uckan, Duygu
Cetin, Mualla
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2010, 27 (07) : 517 - 528
[32] A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
David Martínez-Cuadrón
Blanca Boluda
Pilar Martínez
Juan Bergua
Rebeca Rodríguez-Veiga
Jordi Esteve
Susana Vives
Josefina Serrano
Belen Vidriales
Olga Salamero
Lourdes Cordón
Amparo Sempere
Ana Jiménez-Ubieto
Julio Prieto-Delgado
Marina Díaz-Beyá
Ana Garrido
Celina Benavente
José Antonio Pérez-Simón
Federico Moscardó
Miguel A. Sanz
Pau Montesinos
Annals of Hematology, 2018, 97 : 763 - 772
[33] FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients
Delia, Mario
Pastore, Domenico
Cariuccio, Paola
Paseiolla, Crescenza
Ricco, Alessandra
Rossi, Antonella Russo
Casieri, Paola
Mestice, Anna
Albano, Francesco
Specchia, Giorgina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11): : 767 - 773
[34] Cladribine, Idarubicin, Cytarabine (araC), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Reville, Patrick K.
Kantarjian, Hagop M.
Borthakur, Gautam
Yilmaz, Musa
Montalban-Bravo, Guillermo
DiNardo, Courtney D.
Andreeff, Michael
Daver, Naval
Jain, Nitin
Kornblau, Steven M.
Jabbour, Elias
Short, Nicholas J.
Alvarado, Yesid
Ohanian, Maro
Bose, Prithviraj
Masarova, Lucia
Wang, Sa A.
Tidwell, Rebecca S. S.
Estrov, Zeev E.
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2020, 136
[35] Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
Tsimberidou, A
Estey, E
Cortes, J
Thomas, D
Faderl, S
Verstovsek, S
Garcia-Manero, G
Keating, M
Albitar, M
O'Brien, S
Kantarjian, H
Giles, F
CANCER, 2003, 97 (06) : 1481 - 1487
[36] FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia
Huhmann, IM
Watzke, HH
Geissler, K
Gisslinger, H
Jager, U
Knobl, P
Pabinger, I
Korninger, L
Mannhalter, C
Mitterbauer, G
Schwarzinger, I
Kalhs, P
Haas, OA
Lechner, K
ANNALS OF HEMATOLOGY, 1996, 73 (06) : 265 - 271
[37] The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
Ossenkoppele, GJ
Graveland, WJ
Sonneveld, P
Daenen, SMGJ
Biesma, DH
Verdonck, LF
Schaafsma, R
Westveer, PHM
Peters, F
Noordhuis, P
Muus, P
van der Holt, R
Delforge, M
Löwenberg, B
Verhoef, GEG
BLOOD, 2004, 103 (08) : 2908 - 2913
[38] A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martinez-Cuadron, David
Boluda, Blanca
Martinez, Pilar
Bergua, Juan
Rodriguez-Veiga, Rebeca
Esteve, Jordi
Vives, Susana
Serrano, Josefina
Vidriales, Belen
Salamero, Olga
Cordon, Lourdes
Sempere, Amparo
Jimenez-Ubieto, Ana
Prieto-Delgado, Julio
Diaz-Beya, Marina
Garrido, Ana
Benavente, Celina
Antonio Perez-Simon, Jose
Moscardo, Federico
Sanz, Miguel A.
Montesinos, Pau
ANNALS OF HEMATOLOGY, 2018, 97 (05) : 763 - 772
[39] FLUDARABINE, CYTARABINE AND IDARUBICIN FOR INDUCTION TREATMENT OF POOR-RISK ACUTE MYELOID LEUKEMIA
Villa, M. R.
Izzo, G. Nitrato
Gagliardi, A.
Improta, S.
Mastrullo, L.
HAEMATOLOGICA, 2015, 100 : 81 - 81
[40] Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
David Martínez-Cuadrón
Blanca Boluda
Pilar Martínez
Juan Bergua
Rebeca Rodríguez-Veiga
Jordi Esteve
Susana Vives
Josefina Serrano
Belen Vidriales
Olga Salamero
Lourdes Cordón
Amparo Sempere
Ana Jiménez-Ubieto
Julio Prieto-Delgado
Marina Díaz-Beyá
Ana Garrido
Celina Benavente
José Antonio Pérez-Simón
Federico Moscardó
Miguel A. Sanz
Pau Montesinos
Annals of Hematology, 2018, 97 : 923 - 923

← 1 2 3 4 5 →